Original VE | Sensitivity analyses | ||||||||
---|---|---|---|---|---|---|---|---|---|
VE for lab-confirmed cases | VE for epi-linked cases | ||||||||
Age Group | VE% (95% CI) | Vaccinated cases | Confirmeda cases | PCV (95% CI) | VE% (95% CI) | Vaccinated cases | Confirmeda cases | PCV (95% CI) | VE% (95% CI) |
< 9 mob | – | 0 | 2 | 0.00 (0.00–0.84) | – | 1 | 47 | 0.02 (0.00–0.11) | – |
9–11 mo | 87.3 (71.0–95.2) | 1 | 3 | 0.33 (0.01–0.91) | 68.3 (−509–99.5) | 6 | 39 | 0.15 (0.06–0.31) | 88.5 (72.1–96.1) |
12–23 mo | 96.2 (92.6–98.3) | 1 | 12 | 0.08 (0.00–0.38) | 95.9 (71.5–99.9) | 8 | 106 | 0.08 (0.03–0.14) | 96.3 (92.4–98.4) |
24–35 mo | 97.3 (95.1–98.7) | 0 | 11 | 0.00 (0.00–0.28) | 100.0 (92.4–100.0) | 12 | 86 | 0.14 (0.07–0.23) | 96.9 (94.3–98.5) |
36–47 mo | 98.6 (96.7–99.6) | 0 | 7 | 0.00 (0.00–0.41) | 100.0 (86.8–100.0) | 5 | 68 | 0.07 (0.02–0.16) | 98.5 (96.3–99.5) |
48–59 mo | 89.2 (77.9–95.2) | 1 | 8 | 0.13 (0.00–0.51) | 94.0 (53.0–99.9) | 9 | 41 | 0.22 (0.11–0.38) | 88.1 (74.5–95.0) |
60–71 mo | 99.5 (98.3–99.9) | 0 | 7 | 0.00 (0.00–0.41) | 100.0 (95.6–100.0) | 3 | 31 | 0.10 (0.02–0.26) | 99.3 (97.8–99.9) |
Overall | 98.4 (97.8–98.8) | 3 | 50 | 0.06 (0.01–0.17) | 99.1 (97.2–99.8) | 44 | 418 | 0.11 (0.08–0.14) | 98.3 (97.7–98.8) |